This event is co-sponsored with the Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics and the Harvard Law School Office of Career Services
Executive Vice President and General Counsel;
Business Unit Lead, Consumer Healthcare;
President and General Manager, Nutrition
Amy Schulman is an innovative, results-focused leader, as well as a champion for diversity and women's professional advancement. Since 2008 she has led the Pfizer Legal Division which handles some of the most complex, challenging legal matters within a highly regulated industry. As of August 2012, Ms. Schulman also leads Pfizer's Consumer Healthcare (PCH)—a global $4 billion business, which operates in more than 90 countries. In 2010, Ms. Schulman took over responsibility for Pfizer Nutrition—a $2.1 billion, global business and leading provider of infant formulas and other nutritional products in more than 60 countries. She led the business to increased profitably and above market performance and was instrumental in the agreement to sell the business to Nestlý for $11.85 billion, a sale currently under regulatory review. At Pfizer, Ms. Schulman devised a groundbreaking approach to engaging outside counsel that transforms the traditional billable-hour model and produces better results for the company and its firms. Ms. Schulman joined Pfizer as general counsel in June 2008, when the company was exploring the purchase of Wyeth Pharmaceuticals. She played a key role in the negotiations leading up to what became the largest pharmaceutical acquisition in history. Ms. Schulman is executive sponsor of Pfizer's Global Women's Council, where she helps shape efforts to increase diversity and expand opportunities for both women and men across the company. In part due to the parity programs Ms. Schulman helps to lead, Pfizer has seen a significant increase of women in senior level jobs from 2009 to 2011.
Senior Vice President and General Counsel
Mark Nance joined Mylan as senior vice president and general counsel in early 2012. Mylan Inc. which ranks among the leading diversified generic and specialty pharmaceutical companies in the world provide products to customers in more than 150 countries. Previously he served as the general counsel of General Electric Company’s pharmaceutical business, which specializes in diagnostic pharmaceuticals and other high value diagnostic technologies. Mr. Nance graduated from the University of Missouri and was commissioned an officer in the United States Marine Corps where he served globally in various roles for several years. Mr. Nance then attended Cornell Law School and upon graduation entered private practice with a large law firm specializing in M&A and securities work. He left the law firm to join a series of start-up and emerging technology companies in the IT and biotech fields. During this time, he also served as an advisor to the Chairman of the United States Federal Trade Commission specializing in areas of technology and antitrust policy. Mr. Nance is a member of the U.S. National Science Advisory Board for Biosecurity where he chaired the Codes of Conduct in the Life Sciences working group and is a board member of the Alliance for the Prudent Use of Antibiotics and the Johns Hopkins University Carey School of Business Board of Corporate Advisors.
Questions? Email us